Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis: CLEAR Interim Results
Open Access
- 31 December 2018
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Rheumatology Journal
- Vol. 12 (1) , 323-331
Abstract
Background: Worldwide, leflunomide is a commonly used Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It can be used as a monotherapy or in combination with other DMARDs to inhibit the production of inflammatory cells and accordingly reduce inflammation. Objectives: CLEAR is a multi-centric study that aims to assess the clinical efficacy and safety of leflunomide as first-line and/or add-on therapy to other DMARDs with or without steroids in Egyptian patients with active Rheumatoid Arthritis (RA). Methods: Egyptian patients with active RA for whom leflunomide was prescribed at physicians’ discretion were observed for 12 weeks. Clinical Disease Activity Index (CDAI) score, and Health Assessment Questionnaire Disability Index (HAQ-DI) score were acquired thrice during this period. This study was registered on clinicaltrials.gov (NCT03599986). Results: Interim analysis of the data collected from 337 patients (in 21 centers) showed a statistically significant decrease in the mean total CDAI score throughout the first 12 weeks of treatment (pp<0.001) was also observed in HAQ-DI, as the mean ±SD score decreased from 1.46 ±0.69 at baseline to reach 0.67 ±0.54 at week 12 (% reduction: 56.11 ±27.59). Conclusion: Results of the interim analysis suggest that treatment of Egyptian patients with active RA with leflunomide (as first-line and/or add-on therapy to other DMARDs with or without steroids) for 12 weeks may be effective in terms of CDAI score and HAQ-DI score reduction and may offer an alternative for patients who experienced resistance, inadequate response or intolerance to other DMARDs.Keywords
This publication has 15 references indexed in Scilit:
- Quality of life assessment in Egyptian rheumatoid arthritis patients: Relation to clinical features and disease activityThe Egyptian Rheumatologist, 2016
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis & Rheumatology, 2015
- Prevalence of Arthritis in Africa: A Systematic Review and Meta-AnalysisPLOS ONE, 2015
- Methotrexate: A Gold Standard for Treatment of Rheumatoid ArthritisJournal of Pain & Palliative Care Pharmacotherapy, 2014
- Prevalence of vitamin D deficiency in Egyptian rheumatoid arthritis patients: correlation with disease activity, functional disability, and bone mineral densityEgyptian Rheumatology and Rehabilitation, 2014
- Prevalence of juvenile idiopathic arthritis in Sharkia Governorate, Egypt: epidemiological studyRheumatology International, 2013
- Efficacy and safety of leflunomide in DMARD-naive patients with early rheumatoid arthritis: comparison of a loading and a fixed-dose regimenRheumatology, 2013
- Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritisOpen Access Rheumatology: Research and Reviews, 2010
- Leflunomide in the treatment of patients with early rheumatoid arthritis—results of a prospective non-interventional studyClinical Rheumatology, 2010
- Leflunomide in the treatment of rheumatoid arthritis and other autoimmune disordersInternational Journal of Rheumatic Diseases, 2004